Journal Mobile Options
Table of Contents
Vol. 70, No. 1, 2004
Issue release date: 2004
Digestion 2004;70:49–54

Inflammatory Bowel Disease-Specific Autoantibodies in HLA-B27-Associated Spondyloarthropathies: Increased Prevalence of ASCA and pANCA

Török H.-P. · Glas J. · Gruber R. · Brumberger V. · Strasser C. · Kellner H. · Märker-Hermann E. · Folwaczny C.
aMedizinische Poliklinik, bChirurgische Klinik und Poliklinik, Standort Innenstadt, Ludwig-Maximilians-Universität, München, und cKlinik Innere Medizin IV, Dr.-Horst-Schmidt-Kliniken, Wiesbaden, Deutschland

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Aims: An association between inflammatory bowel disease (IBD) and spondyloarthropathies (SpA) has repeatedly been reported. The aim of the present study was to investigate whether serologic markers of IBD, e.g. antibodies against Saccharomyces cerevisiae (ASCA), antibodies against exocrine pancreas (PAB) and perinuclear antineutrophil cytoplasmic antibodies (pANCA) are present in HLA-B27-associated SpA. Methods: 87 patients with HLA-B27-positive SpA and 145 controls were tested for ASCA, PAB and pANCA employing ELISA or indirect immunofluorescence, respectively. Antibody-positive patients were interviewed regarding IBD-related symptoms using a standardized questionnaire. Results/Conclusion: When compared to the controls, ASCA IgA but not ASCA IgG levels were significantly increased in patients with SpA, in particular in ankylosing spondylitis (AS) and undifferentiated SpA (uSpA). pANCA were found in increased frequency in patients with SpA whereas PAB were not detected. The existence of autoantibodies was not associated with gastrointestinal symptoms but sustains the presence of a pathophysiological link between bowel inflammation and SpA.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. De Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M: Spondyloarthropathy is underestimated in inflammatory bowel disease: Prevalence and HLA association. J Rheumatol 2000;27:2860–2865.
  2. Salvarani C, Vlachonikolis IG, van der Heijde DM, Fornaciari G, Macchioni P, Beltrami M, Olivieri I, Di Gennaro F, Politi P, Stockbrugger RW, Russel MG: European Collaborative IBD Study Group: Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol 2001;36:1307–1313.
  3. Palm O, Moum B, Ongre A, Gran JT: Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: A population study (the IBSEN study). J Rheumatol 2002;29:511–515.
  4. Steer S, Jones H, Hibbert J, Kondeatis E, Vaughan R, Sanderson J, Gibson T: Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn’s disease. J Rheumatol 2003;30:518–522.
  5. Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppala K: High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 1994;37:23–31.
  6. Mielants H, Veys EM, Cuvelier C, de Vos M: Ileocolonoscopic findings in seronegative spondyloarthropathies. Br J Rheumatol 1988;27:95–105.
  7. Mielants H, Veys EM, De Vos M, Cuvelier C, Goemaere S, De Clercq L, Schatteman L, Elewaut D: The evolution of spondyloarthropathies in relation to gut histology I. Clinical aspects. J Rheumatol 1995;22:2266–2272.
  8. De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E: Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996;110:1696–1703.
  9. Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, Schatteman L, Gyselbrecht L, Elewaut D: The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 1995;22:2279–2284.
  10. De Vos M, Cuvelier C, Mielants H, Veys E, Barbier F, Elewaut A: Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology 1989;96:339–344.
  11. Porzio V, Biasi G, Corrado A, De Santi M, Vindigni C, Viti S, Bayeli PF, Marcolongo R: Intestinal histological and ultrastructural inflammatory changes in spondyloarthropathy and rheumatoid arthritis. Scand J Rheumatol 1997;26:92–98.
  12. Simenon G, Van Gossum A, Adler M, Rickaert F, Appelboom T: Macroscopic and microscopic gut lesions in seronegative spondyloarthropathies. J Rheumatol 1990;17:1491–1494.
  13. Lee YH, Ji JD, Kim JS, Bak YT, Lee CH, Kim CH, Chae YS, Song GG: Ileocolonoscopic and histologic studies of Korean patients with ankylosing spondylitis. Scand J Rheumatol 1997;26:473–476.
  14. Grillet B, de Clerck L, Dequeker J, Rutgeerts P, Geboes K: Systematic ileocolonoscopy and bowel biopsy study in spondylarthropathy. Br J Rheumatol 1987;26:338–340.
  15. Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR, Parratt D: Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease. BMJ 1988;297:1105–1106.
  16. Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Poulain D: Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: Prevalence and diagnostic role. Gut 1998;42:788–791.
  17. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG: Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998;115:822–829.
  18. Stocker W, Otte M, Ulrich S, Normann D, Finkbeiner H, Stocker K, Jantschek G, Scriba PC: Autoimmunity to pancreatic juice in Crohn’s disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease. Scand J Gastroenterol 1987;139:41–52.
  19. Folwaczny C, Noehl N, Endres SP, Loeschke K, Fricke H: Antineutrophil and pancreatic autoantibodies in first-degree relatives of patients with inflammatory bowel disease. Scand J Gastroenterol 1998;33:523–528.
  20. Duerr RH, Targan SR, Landers CJ, Sutherland LR, Shanahan F: Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology 1991;100:1590–1596.
  21. Cambridge G, Rampton DS, Stevens TR, McCarthy DA, Kamm M, Leaker B: Anti-neutrophil antibodies in inflammatory bowel disease: Prevalence and diagnostic role. Gut 1992;33:668–674.
  22. Lee JC, Lennard-Jones JE, Cambridge G: Antineutrophil antibodies in familial inflammatory bowel disease. Gastroenterology 1995;108:428–433.
  23. Annese V, Andreoli A, Andriulli A, Dinca R, Gionchetti P, Latiano A, Lombardi G, Piepoli A, Poulain D, Sendid B, Colombel JF: Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn’s disease and ulcerative colitis: A GISC study. Am J Gastroenterol 2001;96:2407–2412.
  24. Glas J, Torok HP, Vilsmaier F, Herbinger KH, Hoelscher M, Folwaczny C: Anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease and their first-degree relatives: Potential clinical value. Digestion 2002;66:173–177.
  25. Folwaczny C, Noehl N, Tschop K, Endres SP, Heldwein W, Loeschke K, Fricke H: Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives. Gastroenterology. 1997;113:101–106.
  26. Folwaczny C, Noehl N, Endres SP, Heldwein W, Loeschke K, Fricke H: Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives. Dig Dis Sci 1997;42:1593–1597.
  27. Vermeire S, Joossens S, Peeters M, Monsuur F, Marien G, Bossuyt X, Groenen P, Vlietinck R, Rutgeerts P. Comparative study of ASCA (anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 2001;120:827–833.
  28. Hoffman IE, Demetter P, Peeters M, De Vos M, Mielants H, Veys EM, De Keyser F: Anti-Saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis 2003;62:455–459.
  29. Koh WH, Dunphy J, Dixey J, Calin A, McHugh NJ, Maddison PJ: Atypical antineutrophil cytoplasmic antibodies in patients with ankylosing spondylitis. Br J Rheumatol 1995;34:695–696.
  30. Weinerth JD, Stoffel MP, Csernok E, Gross WL: Are antineutrophil cytoplasmic antibodies associated with spondyloarthropathies? Br J Rheumatol 1996;35:1032–1033.
  31. Locht H, Peen E, Skogh T: Antineutrophil cytoplasmic antibodies in reactive arthritis. J Rheumatol 1995;22:2304–2306.
  32. Gordon LK, Eggena M, Holland GN, Weisz JM, Braun J: pANCA antibodies in patients with anterior uveitis: Identification of a marker antibody usually associated with ulcerative colitis. J Clin Immunol 1998;18:264–271.
  33. Lionetti P, Pupi A, Veltroni M, Fonda C, Cavicchi MC, Azzari C, Falcini F: Evidence of subclinical intestinal inflammation by 99m-technetium leukocyte scintigraphy in patients with HLA-B27-positive juvenile onset active spondyloarthropathy. J Rheumatol 2000;27:1538–1541.
  34. Smale S, Natt RS, Orchard TR, Russell AS, Bjarnason I: Inflammatory bowel disease and spondylarthropathy. Arthritis Rheum 2001;44:2728–2736.
  35. Vermeire S, Peeters M, Vlietinck R, Joossens S, Den Hond E, Bulteel V, Bossuyt X, Geypens B, Rutgeerts P: Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001;7:8–15.
  36. Mielants H, De Vos M, Goemaere S, Schelstraete K, Cuvelier C, Goethals K, Maertens M, Ackerman C, Veys EM: Intestinal mucosal permeability in inflammatory rheumatic diseases. II. Role of disease. J Rheumatol 1991;18:394–400.
  37. Baeten D, De Keyser F, Mielants H, Veys EM: Immune linkages between inflammatory bowel disease and spondyloarthropathies. Curr Opin Rheumatol 2002;14:342–347.
  38. Demetter P, Baeten D, De Keyser F, De Vos M, Van Damme N, Verbruggen G, Vermeulen S, Mareel M, Elewaut D, Mielants H, Veys EM, Cuvelier CA: Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex. Ann Rheum Dis 2000;59:211–216.
  39. Demetter P, Van Huysse JA, De Keyser F, Van Damme N, Verbruggen G, Mielants H, De Vos M, Veys EM, Cuvelier CA: Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis. J Pathol 2002;198:517–522.
  40. Van Damme N, De Vos M, Baeten D, Demetter P, Mielants H, Verbruggen G, Cuvelier C, Veys EM, De Keyser F: Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy. Ann Rheum Dis 2001;60:495–499.
  41. Demetter P, De Vos M, De Keyser F, Van de Velde S, Baeten D, Van Damme N, Verbruggen G, Mielants H, Veys EM, Cuvelier CA: Increased number of macrophages in non-inflamed colon of patients with spondyloarthropathy, a human model of early Crohn’s disease. Gastroenterology 2000; 118:A342.
  42. May E, Marker-Hermann E, Wittig BM, Zeitz M, Meyer zum Buschenfelde KH, Duchmann R: Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology 2000;119:1745–1755.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50